Impact BioMedical Overview
Impact BioMedical (IBO) has a P/E ratio of -4.48, below the Healthcare sector average of 25.72.
Get informed when a big investor buys or sells
+ Follow-4.48
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Impact BioMedical (IBO) currently reports a P/E ratio of -4.48. That is below the Healthcare sector average of 25.72. Use the charts on this page to explore Impact BioMedical's P/E ratio history and peer comparisons.
Impact BioMedical's P/E ratio of -4.48 is lower than the Healthcare sector average of 25.72. That is roughly 117.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Impact BioMedical's market price to a fundamental measure such as earnings, sales, or book value. At -4.48, IBO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -4.48, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.72. From there, open related valuation or income-statement pages for Impact BioMedical, and consider following IBO for alerts when major investors trade the stock.
Impact BioMedical is classified in the Healthcare sector. On P/E ratio, it currently shows -4.48 versus a sector average near 25.72. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBO with unrelated industries.
